Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd demonstrates a robust outlook due to the promising commercial stage of its drug candidate VTAMA for treating plaque psoriasis, along with positive Phase 3 results for brepocitinib in dermatomyositis (DM), which highlights its efficacy and a significant improvement in delivery methods compared to existing therapies. The company has raised revenue estimates for IMVT-1402 in Graves' Disease, reflecting strong investor sentiment towards its clinical advancements and the potential for successful commercialization of its diverse pipeline, including Batoclimab, which is uniquely positioned as a disease-modifying therapy in Graves' patients. Overall, these factors contribute to a favorable assessment of Roivant's growth prospects within the biopharmaceutical sector.

Bears say

The financial outlook for Roivant Sciences is negatively impacted by the recent failure of key drug candidates in clinical trials, including the IMVT assets and brepocitinib, which raises concerns about the company's pipeline viability and long-term growth potential. Additionally, the uncertainty surrounding the efficacy and safety of remaining candidates, such as the off-target effects related to TSHR antagonism, adds further risk to future product development. The prevalence of unmet medical needs in key indications underscores the potential challenges Roivant faces in differentiating its treatments and capturing market share amid increasing competition.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.